QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(IRS Employer Identification No.) | ||
(Address Of Principal Executive Offices) |
(Zip Code) |
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer |
☒ | Smaller reporting company | ||||
Emerging growth company |
Page |
||||
1 | ||||
2 | ||||
2 | ||||
3 | ||||
4 | ||||
6 | ||||
7 | ||||
39 | ||||
58 | ||||
58 | ||||
59 | ||||
59 | ||||
59 | ||||
59 | ||||
59 | ||||
59 | ||||
59 |
• | our projected financial information, growth rate and market opportunity; |
• | changes in applicable laws or regulations; |
• | our ability to raise financing in the future; |
• | our success in retaining or recruiting, or changes required in, our officers, key employees or directors; |
• | our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business; |
• | our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; |
• | our financial performance; |
• | our ability to expand or maintain its existing customer base; and |
• | the effect of global economic conditions or political transitions on our customers and their ability to continue to purchase our products. |
Item 1. |
Consolidated Financial Statements (Unaudited) |
September 30, 2021 (Unaudited) |
December 31, 2020 |
|||||||
ASSETS |
||||||||
CURRENT ASSETS: |
||||||||
Cash and cash equivalents |
$ | $ | ||||||
Accounts receivable—Net of allowances of $ |
||||||||
Income taxes receivable |
||||||||
Deferred contract costs |
||||||||
Other current assets |
||||||||
|
|
|
|
|||||
Total current assets |
||||||||
|
|
|
|
|||||
SOFTWARE, EQUIPMENT, AND PROPERTY—Net |
||||||||
OPERATING LEASE ASSETS |
— | |||||||
INTANGIBLE ASSETS—Net |
||||||||
GOODWILL |
||||||||
DEFERRED FINANCING FEES, REVOLVER—Net |
||||||||
DEFERRED CONTRACT COSTS |
||||||||
EQUITY METHOD INVESTMENT |
— | |||||||
OTHER ASSETS |
||||||||
|
|
|
|
|||||
TOTAL |
$ |
$ |
||||||
|
|
|
|
|||||
LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY |
||||||||
CURRENT LIABILITIES: |
||||||||
Accounts payable |
$ | $ | ||||||
Accrued expenses |
||||||||
Income taxes payable |
||||||||
Current portion of long-term debt |
||||||||
Current portion of long-term licensing agreement—Net |
||||||||
Operating lease liabilities |
— | |||||||
Deferred revenues |
||||||||
|
|
|
|
|||||
Total current liabilities |
||||||||
|
|
|
|
|||||
LONG-TERM DEBT: |
||||||||
First Lien Term Loan—Net |
— | |||||||
Term B Loan—Net |
— | |||||||
|
|
|
|
|||||
Total long-term debt |
||||||||
|
|
|
|
|||||
DEFERRED INCOME TAXES—Net |
||||||||
LONG-TERM LICENSING AGREEMENT—Net |
||||||||
OPERATING LEASE LIABILITIES |
— | |||||||
WARRANT LIABILITIES |
— | |||||||
OTHER LIABILITIES |
||||||||
|
|
|
|
|||||
Total liabilities |
||||||||
|
|
|
|
|||||
COMMITMENTS AND CONTINGENCIES (Notes 22 and 23) |
||||||||
MEZZANINE EQUITY: |
||||||||
Redeemable non-controlling interest |
||||||||
STOCKHOLDERS’ EQUITY: |
||||||||
Preferred stock, $ |
||||||||
Common stock—$ |
||||||||
Additional paid-in capital |
||||||||
Accumulated deficit |
( |
) | ( |
) | ||||
Accumulated other comprehensive loss |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Total stockholders’ equity |
||||||||
|
|
|
|
|||||
TOTAL |
$ |
$ |
||||||
|
|
|
|
For the Three Months Ended September 30, |
For the Nine Months Ended September 30, |
|||||||||||||||
2021 |
2020 |
2021 |
2020 |
|||||||||||||
REVENUES |
$ | $ | $ | $ | ||||||||||||
COST OF REVENUES |
||||||||||||||||
Cost of revenues, exclusive of amortization of acquired technologies |
||||||||||||||||
Amortization of acquired technologies |
||||||||||||||||
Total cost of revenues |
||||||||||||||||
GROSS PROFIT |
||||||||||||||||
OPERATING EXPENSES: |
||||||||||||||||
Research and development |
||||||||||||||||
Selling and marketing |
||||||||||||||||
General and administrative |
||||||||||||||||
Amortization of intangible assets |
||||||||||||||||
Total operating expenses |
||||||||||||||||
OPERATING (LOSS) INCOME |
( |
) | ( |
) | ||||||||||||
INTEREST EXPENSE |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
GAIN (LOSS) ON CHANGE IN FAIR VALUE OF INTEREST RATE SWAPS |
( |
) | ||||||||||||||
CHANGE IN FAIR VALUE OF WARRANT LIABILITIES |
( |
) | — | ( |
) | — | ||||||||||
LOSS ON EARLY EXINGUISHMENT OF DEBT |
( |
) | — | ( |
) | ( |
) | |||||||||
OTHER (EXPENSE) INCOME—Net |
( |
) | ||||||||||||||
PRETAX (LOSS) INCOME |
( |
) | ( |
) | ( |
) | ||||||||||
INCOME TAX BENEFIT (PROVISION) |
( |
) | ||||||||||||||
NET (LOSS) INCOME INCLUDING NON-CONTROLLING INTEREST |
( |
) | ( |
) | ( |
) | ||||||||||
Less: net (loss) income attributable to non-controlling interest |
||||||||||||||||
NET (LOSS) INCOME ATTRIBUTABLE TO CCC INTELLIGENT SOLUTIONS HOLDINGS INC. |
$ | ( |
) | $ | $ | ( |
) | $ | ( |
) | ||||||
Net (loss) income per share attributable to common stockholders: |
||||||||||||||||
Basic |
$ | ( |
) | $ | $ | ( |
) | $ | ( |
) | ||||||
Diluted |
$ | ( |
) | $ | $ | ( |
) | $ | ( |
) | ||||||
Weighted-average shares used in computing net (loss) income per share attributable to common stockholders: |
||||||||||||||||
Basic |
||||||||||||||||
Diluted |
||||||||||||||||
COMPREHENSIVE (LOSS) INCOME: |
||||||||||||||||
Net (loss) income including non-controlling interest |
( |
) | ( |
) | ( |
) | ||||||||||
Other comprehensive income (loss)—Foreign currency translation adjustment |
( |
) | ||||||||||||||
COMPREHENSIVE (LOSS) INCOME INCLUDING NON-CONTROLLING INTEREST |
( |
) | ( |
) | ( |
) | ||||||||||
Less: comprehensive (loss) income attributable to non-controlling interest |
||||||||||||||||
COMPREHENSIVE (LOSS) INCOME ATTRIBUTABLE TO CCC INTELLIGENT SOLUTIONS HOLDINGS INC. |
$ | ( |
) | $ | $ | ( |
) | $ | ( |
) | ||||||
Redeemable |
||||||||||||||||||||||||||||||||||||||||||||||||||||
Non-Controlling |
Issued Preferred Stock |
CCCIS Issued Common Stock |
Retained |
Accumulated |
||||||||||||||||||||||||||||||||||||||||||||||||
Interest |
Series A |
Series B |
Common Stock |
Additional |
Earnings |
Other |
Total |
|||||||||||||||||||||||||||||||||||||||||||||
Number of |
Par |
Number of |
Par |
Number of |
Par |
Number of |
Par |
Paid-In |
(Accumulated |
Comprehensive |
Stockholders’ |
|||||||||||||||||||||||||||||||||||||||||
Shares |
Value |
Shares |
Value |
Shares |
Value |
Shares |
Value |
Capital |
Deficit) |
Loss |
Equity |
|||||||||||||||||||||||||||||||||||||||||
BALANCE—December 31, 2020 (as previously reported) |
$ | |
$ | $ | |
$ | |
$ | |
$ | ( |
) | $ | ( |
) | $ | ||||||||||||||||||||||||||||||||||||
Retrospective application of the recapitalization due to Business Combination (Note 3) |
— | — | — | ( |
) | ( |
) | ( |
) | — | ( |
) | — | — | — | |||||||||||||||||||||||||||||||||||||
BALANCE—December 31, 2020, effect of Business Combination (Note 3) |
— | — | — | — | — | — | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock |
— | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation expense |
— | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||
Exercise of stock options—net of tax |
— | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||
Dividend to CCCIS stockholders |
— | — | — | — | — | — | — | — | — | — | ( |
) | — | ( |
) | |||||||||||||||||||||||||||||||||||||
Foreign currency translation adjustment |
— | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
Net loss |
— | — | — | — | — | — | — | — | — | — | ( |
) | — | ( |
) | |||||||||||||||||||||||||||||||||||||
BALANCE—March 31, 2021 |
( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation expense |
— | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
Foreign currency translation adjustment |
— | — | — | — | — | — | — | — | — | — | — | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||
Net income |
— | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
BALANCE—June 30, 2021 |
( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation expense |
— | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
Net equity infusion from the Business Combination |
— | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||
Dividend to CCCIS stockholders |
— | — | — | — | — | — | — | — | — | — | ( |
) | — | ( |
) | |||||||||||||||||||||||||||||||||||||
Deemed distribution to CCCIS option holders |
— | — | — | — | — | — | — | — | — | ( |
) | — | — | ( |
) | |||||||||||||||||||||||||||||||||||||
Company Vesting Shares granted to CCCIS stockholders |
— | — | — | — | — | — | — | — | — | ( |
) | — | — | |||||||||||||||||||||||||||||||||||||||
Foreign currency translation adjustment |
— | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
Net loss |
— | — | — | — | — | — | — | — | — | — | ( |
) | — | ( |
) | |||||||||||||||||||||||||||||||||||||
BALANCE—September 30, 2021 |
$ | |
$ | $ | $ | $ | $ | $ | ( |
) | $ | ( |
) | $ | |
|||||||||||||||||||||||||||||||||||||
Redeemable Non-Controlling |
Issued Preferred Stock |
CCCIS Issued Common Stock |
Retained Earnings |
Accumulated Other |
||||||||||||||||||||||||||||||||||||||||||||||||
Interest |
|
|
Series A |
Series B |
Common Stock |
Additional Paid-In |
Total Stockholders’ |
|||||||||||||||||||||||||||||||||||||||||||||
Number of |
Par |
Number of |
Par |
Number of |
Par |
Number of |
Par |
(Accumulated |
Comprehensive |
|||||||||||||||||||||||||||||||||||||||||||
Shares |
Value |
Shares |
Value |
Shares |
Value |
Shares |
Value |
Capital |
Deficit) |
Loss |
Equity |
|||||||||||||||||||||||||||||||||||||||||
BALANCE—December 31, 2019 |
$ | |
$ | $ | $ | $ | $ | ( |
) | $ | ( |
) | $ | |||||||||||||||||||||||||||||||||||||||
Retrospective application of the recapitalization due to Business Combination (Note 3) |
— | — | — | ( |
) | ( |
) | ( |
) | — | ( |
) | — | — | — | |||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||
BALANCE—December 31, 20 19 , effect of Business Combination (Note 3) |
— | — | — | — | — | — | ( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||||||||
Issuance of non-controlling interest in subsidiary |
— | — | — | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||
Issuance of common stock |
— | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation expense |
— | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
Exercise of stock options—net of tax |
— | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||
Repurchase and cancellation of common stock |
— | — | — | — | — | — | — | ( |
) | — | ( |
) | — | — | ( |
) | ||||||||||||||||||||||||||||||||||||
Foreign currency translation adjustment |
— | — | — | — | — | — | — | — | — | — | — | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||
Net loss |
— | — | — | — | — | — | — | — | — | — | ( |
) | — | ( |
) | |||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||
BALANCE—March 31, 2020 |
( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation expense |
— | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
Exercise of stock options—net of tax |
— | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||
Repurchase and cancellation of common stock |
— | — | — | — | — | — | ( |
) | — | ( |
) | — | — | ( |
) | |||||||||||||||||||||||||||||||||||||
Foreign currency translation adjustment |
— | — | — | — | — | — | — | — | — | — | — | ( |
) | ( |
) | |||||||||||||||||||||||||||||||||||||
Net loss |
— | — | — | — | — | — | — | — | — | — | ( |
) | — | ( |
) | |||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||
BALANCE—June 30, 2020 |
( |
) | ( |
) | ||||||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation expense |
— | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
Exercise of stock options—net of tax |
— | — | — | — | — | — | — | — | — | — | ||||||||||||||||||||||||||||||||||||||||||
Repurchase and cancellation of common stock |
— | — | — | — | — | — | — | ( |
) | — | ( |
) | — | — | ( |
) | ||||||||||||||||||||||||||||||||||||
Foreign currency translation adjustment |
— | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
Net loss |
— | — | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||
BALANCE—September 30, 2020 |
$ | |
$ | $ | $ | $ | $ | $ | ( |
) | $ | ( |
) | $ | ||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Nine Months Ended September 30, |
||||||||
2021 |
2020 |
|||||||
CASH FLOWS FROM OPERATING ACTIVITIES: |
||||||||
Net loss |
$ | ( |
) | $ | ( |
) | ||
Adjustments to reconcile net loss to net cash provided by operating activities: |
||||||||
Depreciation and amortization of software, equipment, and property |
||||||||
Amortization of intangible assets |
||||||||
Deferred income taxes |
( |
) | ( |
) | ||||
Stock-based compensation |
||||||||
Amortization of deferred financing fees |
||||||||
Amortization of discount on debt |
||||||||
Change in fair value of interest rate swaps |
( |
) | ||||||
Change in fair value of warrant liabilities |
— | |||||||
Loss on early extinguishment of debt |
||||||||
Non-cash lease expense |
— | |||||||
Other |
||||||||
Changes in: |
||||||||
Accounts receivable—Net |
( |
) | ( |
) | ||||
Deferred contract costs |
( |
) | ( |
) | ||||
Other current assets |
( |
) | ( |
) | ||||
Deferred contract costs—Non-current |
( |
) | ( |
) | ||||
Other assets |
( |
) | ( |
) | ||||
Operating lease assets |
— | |||||||
Income taxes |
( |
) | ||||||
Accounts payable |
||||||||
Accrued expenses |
( |
) | ||||||
Operating lease liabilities |
( |
) | — | |||||
Deferred revenues |
||||||||
Extinguishment of interest rate swap liability |
( |
) | — | |||||
Other liabilities |
( |
) | ||||||
Net cash provided by operating activities |
||||||||
CASH FLOWS FROM INVESTING ACTIVITIES: |
||||||||
Purchases of software, equipment, and property |
( |
) | ( |
) | ||||
Purchase of equity method investment |
( |
) | — | |||||
Purchase of intangible asset |
( |
) | ( |
) | ||||
Net cash used in investing activities |
( |
) | ( |
) | ||||
CASH FLOWS FROM FINANCING ACTIVITIES: |
||||||||
Proceeds from issuance of non-controlling interest in subsidiary |
— | |||||||
Deemed distribution to CCCIS option holders |
( |
) | — | |||||
Net proceeds from equity infusion from the Business Combination |
— | |||||||
Principal payments on long-term debt |
( |
) | ( |
) | ||||
Proceeds from issuance of long-term debt, net of fees paid to lender |
||||||||
Proceeds from borrowings on revolving lines of credit |
— | |||||||
Repayment of borrowings on revolving lines of credit |
— | ( |
) | |||||
Proceeds from issuance of common stock |
— | |||||||
Payment of fees associated with early extinguishment of long-term debt |
( |
) | ( |
) | ||||
Proceeds from exercise of stock options |
||||||||
Repurchases of common stock |
— | ( |
) | |||||
Dividends to CCCIS stockholders |
( |
) | — | |||||
Net cash used in financing activities |
( |
) | ( |
) | ||||
NET EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS |
( |
) | ||||||
NET CHANGE IN CASH AND CASH EQUIVALENTS |
( |
) | ||||||
CASH AND CASH EQUIVALENTS: |
||||||||
Beginning of period |
||||||||
End of period |
$ | $ | ||||||
NONCASH INVESTING AND FINANCING ACTIVITIES: |
||||||||
Unpaid liability related to software, equipment, and property |
$ | $ | — | |||||
Leasehold improvements acquired by tenant improvement allowance |
$ | $ | — | |||||
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: |
||||||||
Cash paid for interest, excluding extinguishment of interest rate swap liability |
$ | $ | ||||||
Cash received (paid) for income taxes—Net |
$ | ( |
) | $ | ||||
1. |
ORGANIZATION AND NATURE OF OPERATIONS |
2. |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
For the Three Months Ended September 30, |
For the Nine Months Ended September 30, |
|||||||||||||||
2021 |
2020 |
2021 |
2020 |
|||||||||||||
Customer A |
* | * | * | * | ||||||||||||
Customer B |
* | % | * | % |
* | Below 10% |
September 30, 2021 |
December 31, 2020 |
|||||||
Customer A |
% | % | ||||||
Customer B |
% | * |
* | Below 10% |
• | Identification of the contract, or contracts, with a customer |
• | Identification of the performance obligation(s) in the contract |
• | Determination of the transaction price |
• | Allocation of the transaction price to the performance obligation(s) in the contract |
• | Recognition of revenue when, or as a performance obligation is satisfied |
For the Three Months Ended September 30, |
For the Nine Months Ended September 30, |
|||||||||||||||
2021 |
2020 |
2021 |
2020 |
|||||||||||||
Software subscriptions |
$ | $ | $ | $ | ||||||||||||
Other |
||||||||||||||||
Total revenues |
$ | $ | $ | $ | ||||||||||||
3. |
BUSINESS COMBINATION |
• |
the pre-Closing CCCIS stockholders continue to control the Company following the Closing of the Business Combination; |
• |
the board of directors and management of the Company following the Business Combination are composed of individuals associated with CCCIS; |
• |
CCCIS was the larger entity based on historical operating activity, assets, revenues, and employee base at the time of the Closing of the Transactions; and |
• |
the ongoing operations of the Company following the Business Combination comprise those of CCCIS. |
• | each share of CCCIS common stock that was issued and outstanding immediately prior to the Effective Time was automatically canceled and converted into the right to receive shares of the Company’s common stock based on the Exchange Ratio, rounded down to the nearest whole number of shares; |
• | each option to purchase shares of CCCIS common stock, whether vested or unvested, that was outstanding and unexercised as of immediately prior to the Effective Time was assumed by the Company and became an option (vested or unvested, as applicable) to purchase a number of shares of the Company’s common stock equal to the number of shares of CCCIS common stock subject to such option immediately prior to the Effective Time multiplied by the Exchange Ratio, rounded down to the nearest whole number of shares, at an exercise price equal to the exercise price per share of such option immediately prior to the Effective Time divided by the Exchange Ratio and rounded up to the nearest whole cent; |
• | each of Dragoneer’s redeemable Class A ordinary share and Class B ordinary share that was issued and outstanding immediately prior to the Effective Time was exchanged for an equal number of shares of the Company’s common stock. |
Shares issued to Dragoneer public shareholders and Sponsor |
||||
Sponsor Vesting Shares |
||||
Shares issued to Legacy CCC shareholders |
||||
Shares issued to Forward Purchasers |
||||
Shares issued to PIPE Investors |
||||
|
|
|||
Total shares of common stock outstanding immediately following the Business Combination |
||||
|
|
Cash - Dragoneer trust and cash |
$ | |||
Cash - PIPE Financing |
||||
Cash - Forward Purchase Agreements |
||||
Less: transaction costs and advisory fees |
( |
) | ||
|
|
|||
Net cash contibutions from Business Combination |
||||
Less: non-cash fair value of Public Warrants and Private Warrants |
( |
) | ||
|
|
|||
Net equity infusion from Business Combination |
$ | |||
|
|
4. |
REVENUE |
September 30, |
December 31, |
|||||||
2021 |
2020 |
|||||||
Accounts receivables-Net of allowances |
$ | $ | ||||||
Deferred contract costs |
||||||||
Long-term deferred contract costs |
||||||||
Deferred revenues |
||||||||
Other liabilities (deferred revenues, non-current) |
For the Three Months Ended |
For the Nine Months Ended |
|||||||||||||||
September 30, |
September 30, |
|||||||||||||||
2021 |
2020 |
2021 |
2020 |
|||||||||||||
Balance at beginning of period |
$ | $ | $ | $ | ||||||||||||
Revenue recognized 1 |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
Additional amounts deferred 1 |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Balance at end of period |
$ | $ | $ | $ | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Classified as: |
||||||||||||||||
Current |
$ | $ | $ | $ | ||||||||||||
Non-current |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total deferred revenue |
$ | $ | $ | $ | ||||||||||||
|
|
|
|
|
|
|
|
For the Three Months Ended |
For the Nine Months Ended |
|||||||||||||||
September 30, |
September 30, |
|||||||||||||||
2021 |
2020 |
2021 |
2020 |
|||||||||||||
Balance at beginning of period |
$ | $ | $ | $ | ||||||||||||
Costs amortized |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
Additional amounts deferred |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Balance at end of period |
$ | $ | $ | $ | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Classified as: |
||||||||||||||||
Current |
$ | $ | $ | $ | ||||||||||||
Non-current |
||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total deferred contract costs |
$ | $ | $ | $ | ||||||||||||
|
|
|
|
|
|
|
|
5. |
FAIR VALUE MEASUREMENTS |
Expected term (in years) |
||||
Expected volatility |
% | |||
Expected dividend yield |
% | |||
Risk-free interest rate |
% | |||
Fair value at valuation date |
$ |
Liabilities |
Fair Value |
Level 1 |
Level 2 |
Level 3 |
||||||||||||
Public warrants |
$ | $ | $ | — | $ | — | ||||||||||
Private warrants |
— | |||||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total |
$ | $ | $ | $ | ||||||||||||
|
|
|
|
|
|
|
|
Liabilities |
Fair Value |
Level 1 |
Level 2 |
Level 3 |
||||||||||||
Interest rate swaps |
$ | $ | |
$ | $ | |
||||||||||
|
|
|
|
|
|
|
|
|||||||||
Total |
$ | $ | $ | $ | ||||||||||||
|
|
|
|
|
|
|
|
September 30, 2021 |
December 31, 2020 |
|||||||||||||||
Carrying |
Estimated |
Carrying |
Estimated |
|||||||||||||
Description |
Amount |
Fair Value |
Amount |
Fair Value |
||||||||||||
Term B Loan, including current portion |
$ | $ | $ | — | $ | — | ||||||||||
First Lien Term Loan, including current portion |
— | — |
6. |
INCOME TAXES |
7. |
ACCOUNTS RECEIVABLE |
September 30, |
December 31, |
|||||||
2021 |
2020 |
|||||||
Accounts receivable |
$ | $ | ||||||
Allowance for doubtful accounts and sales reserves |
( |
) | ( |
) | ||||
Accounts receivable–net |
$ | $ | ||||||
For the Three Months Ended |
For the Nine Months Ended |
|||||||||||||||
September 30, |
September 30, |
|||||||||||||||
2021 |
2020 |
2021 |
2020 |
|||||||||||||
Balance at beginning of period |
$ | $ | $ | $ | ||||||||||||
Charges to bad debt and sales reserves |
||||||||||||||||
Write-offs, net |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
Balance at end of period |
$ | $ | $ | $ | ||||||||||||
8. |
OTHER CURRENT ASSETS |
September 30, |
December 31, |
|||||||
2021 |
2020 |
|||||||
Prepaid software and equipment maintenance |
$ | $ | ||||||
Prepaid SaaS costs |
||||||||
Prepaid service fees |
||||||||
Prepaid insurance |
||||||||
Non-trade receivables |
||||||||
Other |
||||||||
Total |
$ | $ | ||||||
9. |
SOFTWARE, EQUIPMENT, AND PROPERTY |
September 30, |
December 31, |
|||||||
2021 |
2020 |
|||||||
Software, licenses and database |
$ | $ | ||||||
Computer equipment |
||||||||
Leasehold improvements |
||||||||
Furniture and other equipment |
||||||||
Building and land |
||||||||
Total software, equipment, and property |
||||||||
Less accumulated depreciation and amortization |
( |
) | ( |
) | ||||
Net software, equipment, and property |
$ | $ | ||||||
10. |
LEASES |
For the Three Months Ended |
For the Nine Months Ended |
|||||||
September 30, 2021 |
September 30, 2021 |
|||||||
Operating lease costs |
$ | $ | ||||||
Variable lease costs |
||||||||
Total lease costs |
$ | $ | ||||||
Weighted-average remaining lease term (years) |
||||
Weighted-average discount rate |
% |
For the Three Months Ended |
For the Nine Months Ended |
|||||||
September 30, 2021 |
September 30, 2021 |
|||||||
Cash payments for operating leases |
$ | $ | ||||||
Operating lease assets obtained in exchange for lease liabilities |
Years Ending December 31: |
||||
Remainder of 2021 |
$ | |||
2022 |
||||
2023 |
||||
2024 |
||||
2025 |
||||
Thereafter |
||||
Total Lease Payments |
||||
Less: Interest |
( |
) | ||
Less: Lease incentive recognized as offset to lease liability |
( |
) | ||
Total |
$ | |||
Years Ending December 31: |
||||
2021 |
$ | |||
2022 |
||||
2023 |
||||
2024 |
||||
2025 |
||||
Thereafter |
||||
Total |
$ | |||
11. |
GOODWILL AND INTANGIBLE ASSETS |
Weighted- |
||||||||||||||||||||
Average |
||||||||||||||||||||
Estimated |
Remaining |
Gross |
Net |
|||||||||||||||||
Useful Life |
Useful Life |
Carrying |
Accumulated |
Carrying |
||||||||||||||||
(Years) |
(Years) |
Amount |
Amortization |
Amount |
||||||||||||||||
Intangible assets: |
||||||||||||||||||||
Customer relationships |
$ | $ | ( |
) | $ | |||||||||||||||
Acquired technologies |
( |
) | ||||||||||||||||||
Favorable lease terms |
( |
) | ||||||||||||||||||
Subtotal |
( |
) | ||||||||||||||||||
Trademarks—indefinite life |
— | |||||||||||||||||||
Total intangible assets |
$ | $ | ( |
) | $ | |||||||||||||||
Weighted- |
||||||||||||||||||||
Average |
||||||||||||||||||||
Estimated |
Remaining |
Gross |
Net |
|||||||||||||||||
Useful Life |
Useful Life |
Carrying |
Accumulated |
Carrying |
||||||||||||||||
(Years) |
(Years) |
Amount |
Amortization |
Amount |
||||||||||||||||
Intangible assets: |
||||||||||||||||||||
Customer relationships |
$ | $ | ( |
) | $ | |||||||||||||||
Acquired technologies |
( |
) | ||||||||||||||||||
Favorable lease terms |
( |
) | ||||||||||||||||||
Subtotal |
( |
) | ||||||||||||||||||
Trademarks—indefinite life |
— | |||||||||||||||||||
Total intangible assets |
$ | $ | ( |
) | $ | |||||||||||||||
Years Ending December 31: |
||||
2021 |
$ | |||
2022 |
||||
2023 |
||||
2024 |
||||
2025 |
||||
Thereafter |
||||
Total |
$ | |||
12. |
EQUITY METHOD INVESTMENT |
Equity Method |
||||
Investment |
||||
Equity method investment carrying value at December 31, 2020 |
$ | |||
Cash contributions |
||||
Share of net income (loss) from the Investee |
— | |||
Equity method investment carrying value at September 30, 2021 |
$ | |||
13. |
ACCRUED EXPENSES |
September 30, |
December 31, |
|||||||
2021 |
2020 |
|||||||
Compensation |
$ | $ | ||||||
Professional services |
||||||||
Phantom stock incentive plan |
— | |||||||
Royalties and licenses |
||||||||
Sales tax |
||||||||
Employee insurance benefits |
||||||||
Software license agreement |
— | |||||||
Other |
||||||||
|
|
|
|
|||||
Total |
$ | $ | ||||||
|
|
|
|
14. |
OTHER LIABILITIES |
September 30, |
December 31, |
|||||||
2021 |
2020 |
|||||||
Payroll tax deferment |
$ | $ | ||||||
Software license agreement |
||||||||
Deferred revenue-non-current |
||||||||
Deferred rent |
— | |||||||
Phantom stock incentive plan |
— | |||||||
Fair value of interest rate swaps |
— | |||||||
Other |
— | |||||||
|
|
|
|
|||||
Total |
$ | $ | ||||||
|
|
|
|
15. |
LONG-TERM DEBT |
September 30, |
December 31, |
|||||||
2021 |
2020 |
|||||||
Term B Loan |
$ | |
$ | — | ||||
Term B Loan—discount |
( |
) | — | |||||
Term B Loan—deferred financing fees |
( |
) | — | |||||
|
|
|
|
|||||
Term B Loan—net of discount & fees |
— | |||||||
|
|
|
|
|||||
First Lien Term Loan |
— | |||||||
First Lien Term Loan—discount |
— | ( |
) | |||||
First Lien Term Loan—deferred financing fees |
— | ( |
) | |||||
|
|
|
|
|||||
First Lien Term Loan—net of discount & fees |
— | |||||||
|
|
|
|
|||||
Less: Current portion |
( |
) | ( |
) | ||||
|
|
|
|
|||||
Total long-term debt—net of current portion |
$ | $ | |
|||||
|
|
|
|
16. |
LONG-TERM LICENSING AGREEMENT |
17. |
REDEEMABLE NON-CONTROLLING INTEREST |
18. |
CAPITAL STOCK |
19. |
EMPLOYEE BENEFIT PLANS |
20. |
STOCK INCENTIVE PLANS |
Expected term (in years) |
||||
Expected volatility |
% | |||
Expected dividend yield |
% | |||
Risk-free interest rate |
% | |||
Fair value at valuation date |
$ |
Expected term (in years) |
||||
Expected volatility |
% | |||
Expected dividend yield |
% | |||
Risk-free interest rate |
% | |||
Fair value at valuation date |
$ |
Weighted- |
Weighted-Average |
|||||||||||||||
Average |
Remaining |
Aggregate |
||||||||||||||
Exercise |
Contractual Life |
Intrinsic Value |
||||||||||||||
Shares |
Price |
(in years) |
(in thousands) |
|||||||||||||
Options outstanding—December 31, 2020 |
$ | |
||||||||||||||
Granted |
||||||||||||||||
Exercised |
( |
) | ||||||||||||||
Forfeited and canceled |
( |
) | ||||||||||||||
Options outstanding—September 30, 2021 |
||||||||||||||||
Options exercisable—September 30, 2021 |
||||||||||||||||
Options vested and expected to vest—September 30, 2021 |
||||||||||||||||
For the Three Months Ended September 30, |
For the Nine Months Ended September 30, |
|||||||||||||||
2021 |
2020 |
2021 |
2020 |
|||||||||||||
Cost of revenues |
$ | $ | $ | $ | ||||||||||||
Research and development |
||||||||||||||||
Sales and marketing |
||||||||||||||||
General and administrative |
||||||||||||||||
Total stock-based compensation expense |
$ | |
$ | |
$ | |
$ | |
||||||||
21. |
WARRANTS |
• | at a price of $ |
• | upon a minimum of 30 days prior written notice of redemption to each warrant holder; and |
• | if, and only if, the closing price of the Company’s common shares equals or exceeds $18.00 per share (as adjusted) on the trading day prior to the date on which the Company sends the notice of redemption to the warrant holders. |
• | at a price of $ |
• | upon a minimum of 30 days prior written notice of redemption provided holders will be able to exercise their warrants on a “cashless basis” prior to redemption and receive that number of shares determined by reference to an agreed table based on the redemption date and the fair market value of the Company’s common stock; and |
• | if, and only if, the closing price of the Company’s common stock equals or exceeds $10.00 per share (as adjusted) on the trading day prior to the date on which the Company sends the notice of redemption to the warrant holders. |
22. |
COMMITMENTS |
23. |
LEGAL PROCEEDINGS AND CONTINGENCIES |
24. |
RELATED PARTIES |
25. |
NET (LOSS) INCOME PER |
For the Three Months Ended September 30, |
For the Nine Months Ended September 30, |
|||||||||||||||
2021 |
2020 |
2021 |
2020 |
|||||||||||||
Numerator |
||||||||||||||||
Net (loss) income |
$ | ( |
) | $ | $ | ( |
) | $ | ( |
|||||||
Denominator |
||||||||||||||||
Weighted average shares of common stock - basic |
||||||||||||||||
Dilutive effect of stock options |
||||||||||||||||
Weighted average shares of common stock - diluted |
||||||||||||||||
Net (loss) income per share: |
||||||||||||||||
Basic |
$ | ( |
$ | $ | ( |
$ | ( |
|||||||||
Diluted |
$ | ( |
$ | $ | ( |
$ | ( |
26. |
SEGMENT INFORMATION AND INFORMATION ABOUT GEOGRAPHIC AREAS |
For the Three Months Ended September 30, |
For the Nine Months Ended September 30, |
|||||||||||||||
2021 |
2020 |
2021 |
2020 |
|||||||||||||
United States |
$ | |
$ | |
$ | |
$ | |
||||||||
China |
||||||||||||||||
Total revenues |
$ | $ | $ | $ | ||||||||||||
September 30, 2021 |
December 31, 2020 |
|||||||
United States |
$ | |
$ | |
||||
China |
||||||||
Total software, equipment and property-net |
$ | $ | ||||||
27. |
DIVESTITURE |
28. |
SUBSEQUENT EVENTS |
Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
Quarter Ending |
2021 |
2020 |
||||||||
Software NDR |
March 31 | 106 | % | 105 | % | |||||
June 30 | 110 | % | 103 | % | ||||||
September 30 | 113 | % | 103 | % | ||||||
December 31 | 103 | % |
Quarter Ending |
2021 |
2020 |
||||||||
Software GDR |
March 31 | 98 | % | 98 | % | |||||
June 30 | 98 | % | 98 | % | ||||||
September 30 | 98 | % | 98 | % | ||||||
December 31 | 98 | % |
Three Months Ended September 30, |
Change |
|||||||||||||||
(dollar amounts in thousands, except share and per share data) |
2021 |
2020 |
$ |
% |
||||||||||||
Revenue |
$ | 176,628 | $ | 157,754 | $ | 18,874 | 12.0 | % | ||||||||
Cost of revenue, exclusive of amortization of acquired technologies |
51,273 | 43,879 | 7,394 | 16.9 | % | |||||||||||
Amortization of acquired technologies |
6,580 | 6,576 | 4 | 0.1 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Cost of revenue |
57,853 | 50,455 | 7,398 | 14.7 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Gross profit |
118,775 | 107,299 | 11,476 | 10.7 | % | |||||||||||
Operating expenses: |
||||||||||||||||
Research and development |
67,016 | 26,816 | 40,200 | 149.9 | % | |||||||||||
Selling and marketing |
80,382 | 17,427 | 62,955 | 361.2 | % | |||||||||||
General and administrative |
142,511 | 21,893 | 120,618 | 550.9 | % | |||||||||||
Amortization of intangible assets |
18,078 | 18,078 | — | 0.0 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Total operating expenses |
307,987 | 84,214 | 223,773 | 265.7 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Operating (loss) income |
(189,212 | ) | 23,085 | (212,297 | ) | NM | ||||||||||
Other income (expense): |
||||||||||||||||
Interest expense |
(13,878 | ) | (19,788 | ) | 5,910 | 29.9 | % | |||||||||
Gain on change in fair value of interest rate swaps |
2,007 | 3,894 | (1,887 | ) | -48.5 | % | ||||||||||
Change in fair value of warrant liabilities |
(26,889 | ) | — | (26,889 | ) | NM | ||||||||||
Loss on early extinguishment of debt |
(15,240 | ) | — | (15,240 | ) | NM | ||||||||||
Other (expense) income, net |
(93 | ) | 49 | (142 | ) | NM | ||||||||||
|
|
|
|
|
|
|||||||||||
Total other income (expense) |
(54,093 | ) | (15,845 | ) | (38,248 | ) | -241.4 | % | ||||||||
(Loss) income before income taxes |
(243,305 | ) | 7,240 | (250,545 | ) | NM | ||||||||||
Income tax benefit (provision) |
53,523 | (2,520 | ) | 56,043 | NM | |||||||||||
|
|
|
|
|
|
|||||||||||
Net (loss) income |
$ | (189,782 | ) | $ | 4,720 | $ | (194,502 | ) | NM | |||||||
|
|
|
|
|
|
|||||||||||
Net (loss) income per share attributable to common stockholders: |
||||||||||||||||
Basic |
$ | (0.34 | ) | $ | 0.01 | |||||||||||
Diluted |
$ | (0.34 | ) | $ | 0.01 | |||||||||||
Weighted-average shares used in computing net (loss) income per share attributable to common stockholders: |
||||||||||||||||
Basic |
566,454,782 | 504,212,021 | ||||||||||||||
Diluted |
566,454,782 | 510,694,493 |
Nine Months Ended September 30, |
Change |
|||||||||||||||
(dollar amounts in thousands, except share and per share data) |
2021 |
2020 |
$ |
% |
||||||||||||
Revenue |
$ | 501,205 | $ | 467,677 | $ | 33,528 | 7.2 | % | ||||||||
Cost of revenue, exclusive of amortization of acquired technologies |
128,218 | 135,674 | (7,456 | ) | -5.5 | % | ||||||||||
Amortization of acquired technologies |
19,740 | 19,725 | 15 | 0.1 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Cost of revenue |
147,958 | 155,399 | (7,441 | ) | -4.8 | % | ||||||||||
|
|
|
|
|
|
|||||||||||
Gross profit |
353,247 | 312,278 | 40,969 | 13.1 | % | |||||||||||
Operating expenses: |
||||||||||||||||
Research and development |
128,894 | 82,131 | 46,763 | 56.9 | % | |||||||||||
Selling and marketing |
121,350 | 56,608 | 64,742 | 114.4 | % | |||||||||||
General and administrative |
208,745 | 66,460 | 142,285 | 214.1 | % | |||||||||||
Amortization of intangible assets |
54,232 | 54,232 | — | 0.0 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Total operating expenses |
513,221 | 259,431 | 253,790 | 97.8 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Operating (loss) income |
(159,974 | ) | 52,847 | (212,821 | ) | NM | ||||||||||
Other income (expense): |
||||||||||||||||
Interest expense |
(51,548 | ) | (57,588 | ) | 6,040 | 10.5 | % | |||||||||
Gain (loss) on change in fair value of interest rate swaps |
8,373 | (16,633 | ) | 25,006 | NM | |||||||||||
Change in fair value of warrant liabilities |
(26,889 | ) | — | (26,889 | ) | NM | ||||||||||
Loss on early extinguishment of debt |
(15,240 | ) | (8,615 | ) | (6,625 | ) | -76.9 | % | ||||||||
Other (expense) income, net |
1 | 304 | (303 | ) | -99.7 | % | ||||||||||
|
|
|
|
|
|
|||||||||||
Total other income (expense) |
(85,303 | ) | (82,532 | ) | (2,771 | ) | -3.4 | % | ||||||||
Loss before income taxes |
(245,277 | ) | (29,685 | ) | (215,592 | ) | -726.3 | % | ||||||||
Income tax benefit |
54,227 | 7,191 | 47,036 | 654.1 | % | |||||||||||
|
|
|
|
|
|
|||||||||||
Net loss |
$ | (191,050 | ) | $ | (22,494 | ) | $ | (168,556 | ) | -749.3 | % | |||||
|
|
|
|
|
|
|||||||||||
Net loss per share attributable to common stockholders—basic and diluted |
$ | (0.36 | ) | $ | (0.04 | ) | ||||||||||
Weighted-average shares used in computing net loss per share attributable to common stockholders—basic and diluted |
525,877,533 | 504,062,587 |
Three months ended September 30, |
Nine months ended September 30, |
|||||||||||||||
(amounts in thousands, except percentages) |
2021 |
2020 |
2021 |
2020 |
||||||||||||
Gross Profit |
$ | 118,775 | $ | 107,299 | $ | 353,247 | $ | 312,278 | ||||||||
First Party Clinical Services—Gross Profit |
— | (645 | ) | — | (3,035 | ) | ||||||||||
Amortization of acquired technologies |
6,580 | 6,576 | 19,740 | 19,725 | ||||||||||||
Business combination transaction costs |
905 | — | 905 | — | ||||||||||||
Stock-based compensation |
12,169 | 141 | 12,563 | 380 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Adjusted Gross Profit |
$ | 138,429 | $ | 113,371 | $ | 386,455 | $ | 329,348 | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Gross Profit Margin |
67 | % | 68 | % | 70 | % | 67 | % | ||||||||
Adjusted Gross Profit Margin |
78 | % | 76 | % | 77 | % | 75 | % |
Three months ended September 30, |
Nine months ended September 30, |
|||||||||||||||
(dollar amounts in thousands) |
2021 |
2020 |
2021 |
2020 |
||||||||||||
Net (loss) income |
$ | (189,782 | ) | $ | 4,720 | $ | (191,050 | ) | $ | (22,494 | ) | |||||
Interest expense |
13,878 | 19,788 | 51,548 | 57,588 | ||||||||||||
Income tax provision (benefit) |
(53,523 | ) | 2,520 | (54,227 | ) | (7,191 | ) | |||||||||
Amortization of intangible assets |
18,078 | 18,078 | 54,232 | 54,232 | ||||||||||||
Amortization of acquired technologies—Cost of revenue |
6,580 | 6,576 | 19,740 | 19,725 | ||||||||||||
Depreciation and amortization related to software, equipment and property |
7,694 | 4,496 | 18,161 | 13,039 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
EBITDA |
(197,075 | ) | 56,178 | (101,596 | ) | 114,899 | ||||||||||
(Gain) loss on change in fair value of interest rate swaps |
(2,007 | ) | (3,894 | ) | (8,373 | ) | 16,633 | |||||||||
Change in fair value of warrant liabilities |
26,889 | — | 26,889 | — | ||||||||||||
Stock-based compensation expense |
219,876 | 1,869 | 235,413 | 7,471 | ||||||||||||
Loss on early extinguishment of debt |
15,240 | — | 15,240 | 8,615 | ||||||||||||
Business combination transaction costs |
5,516 | 93 | 10,471 | 93 | ||||||||||||
Lease abandonment |
438 | — | 2,256 | — | ||||||||||||
Lease overlap costs |
924 | — | 2,773 | — | ||||||||||||
Net costs related to divestiture |
338 | — | 2,605 | — | ||||||||||||
First Party Clinical Services—Revenue |
— | (7,830 | ) | — | (26,083 | ) | ||||||||||
First Party Clinical Services—Cost of revenue |
— | 7,185 | — | 23,048 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Adjusted EBITDA |
$ | 70,139 | $ | 53,601 | $ | 185,678 | $ | 144,676 | ||||||||
|
|
|
|
|
|
|
|
Three months ended September 30, |
Nine months ended September 30, |
|||||||||||||||
(dollar amounts in thousands) |
2021 |
2020 |
2021 |
2020 |
||||||||||||
Net (loss) income |
$ | (189,782 | ) | $ | 4,720 | $ | (191,050 | ) | $ | (22,494 | ) | |||||
Amortization of intangible assets |
18,078 | 18,078 | 54,232 | 54,232 | ||||||||||||
Amortization of acquired technologies—Cost of revenue |
6,580 | 6,576 | 19,740 | 19,725 | ||||||||||||
(Gain) loss on change in fair value of interest rate swaps |
(2,007 | ) | (3,894 | ) | (8,373 | ) | 16,633 | |||||||||
Change in fair value of warrant liabilities |
26,889 | — | 26,889 | — | ||||||||||||
Stock-based compensation expense |
219,876 | 1,869 | 235,413 | 7,471 | ||||||||||||
Loss on early extinguishment of debt |
15,240 | — | 15,240 | 8,615 | ||||||||||||
Business combination transaction costs |
5,516 | 93 | 10,471 | 93 | ||||||||||||
Lease abandonment |
438 | — | 2,256 | — | ||||||||||||
Lease overlap costs |
924 | — | 2,773 | — | ||||||||||||
Net costs related to divestiture |
338 | — | 2,605 | — | ||||||||||||
First Party Clinical Services—Revenue |
— | (7,830 | ) | — | (26,083 | ) | ||||||||||
First Party Clinical Services—Cost of revenue |
— | 7,185 | — | 23,048 | ||||||||||||
Tax effect of adjustments |
(72,360 | ) | (5,716 | ) | (89,134 | ) | (26,947 | ) | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Adjusted net income |
$ | 29,730 | $ | 21,081 | $ | 81,062 | $ | 54,293 | ||||||||
Adjusted net income per share attributable to common stockholders |
||||||||||||||||
Basic |
$ | 0.05 | $ | 0.04 | $ | 0.15 | $ | 0.11 | ||||||||
Diluted |
$ | 0.05 | $ | 0.04 | $ | 0.15 | $ | 0.11 | ||||||||
Weighted average shares outstanding |
||||||||||||||||
Basic |
566,454,782 | 504,212,021 | 525,877,533 | 504,062,587 | ||||||||||||
Diluted |
599,675,416 | 510,694,493 | 554,818,300 | 510,252,470 |
Nine months ended September 30, |
||||||||
(dollar amounts in thousands) |
2021 |
2020 |
||||||
Net cash provided by operating activities |
$ | 96,725 | $ | 66,789 | ||||
Net cash used in investing activities |
(35,299 | ) | (24,375 | ) | ||||
Net cash used in financing activities |
(62,917 | ) | (948 | ) | ||||
Net effect of exchange rate change |
(162 | ) | 108 | |||||
|
|
|
|
|||||
Change in cash and cash equivalents |
$ | (1,653 | ) | $ | 41,574 | |||
|
|
|
|
Item 3. |
Quantitative and Qualitative Disclosures About Market Risk |
Item 4. |
Controls and Procedures |
Item 1. |
Legal Proceedings |
Item 1A. |
Risk Factors |
Item 2. |
Unregistered Sales of Equity Securities and Use of Proceeds |
Item 3. |
Defaults upon Senior Securities |
Item 4. |
Mine Safety Disclosures |
Item 5. |
Other Information |
Item 6. |
Exhibits |
* | Schedules and exhibits to this Exhibit omitted pursuant to Regulation S-K Item 601(b)(2). The Registrant agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request. |
† | Schedules and exhibits to this Exhibit omitted pursuant to Regulation S-K Item 601(b)(10). The Registrant agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request. |
Dated: November 10, 2021 | CCC INTELLIGENT SOLUTIONS HOLDINGS INC. | |||||
By: | /s/ Githesh Ramamurthy | |||||
Name: | Githesh Ramamurthy | |||||
Title: | Chief Executive Officer and Chairman of the Board of Directors (Principal Executive Officer) | |||||
Dated: November 10, 2021 | ||||||
By: | /s/ Brian Herb | |||||
Name: | Brian Herb | |||||
Title: | Executive Vice President, Chief Financial and Administrative Officer (Principal Financial Officer) |
Exhibit 31.1
Certification of Chief Executive Officer
Pursuant To
Section 302 of the Sarbanes-Oxley Act of 2002
I, Githesh Ramamurthy, certify that:
1. | I have reviewed this Quarterly Report on Form 10-Q of CCC Intelligent Solutions Holdings Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and |
5. | The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions): |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. |
Dated: November 10, 2021 |
|
/s/ Githesh Ramamurthy | ||||
Githesh Ramamurthy | ||||||
Chief Executive Officer |
Exhibit 31.2
Certification of Chief Financial Officer
Pursuant To
Section 302 of the Sarbanes-Oxley Act of 2002
I, Brian Herb, certify that:
1. | I have reviewed this Quarterly Report on Form 10-Q of CCC Intelligent Solutions Holdings Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and |
5. | The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions): |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. |
Dated: November 10, 2021 | /s/ Brian Herb | |||||
Brian Herb | ||||||
Executive Vice President, Chief Financial and Administrative Officer |
Exhibit 32.1
Certification of Chief Executive Officer
Pursuant To Rule 18 U.S.C. Section 1350
In connection with the Quarterly Report on Form 10-Q of CCC Intelligent Solutions Holdings Inc. (the Company) for the period ended September 30, 2021, as filed with the U.S. Securities and Exchange Commission (the Report), I, Githesh Ramamurthy, Chief Executive Officer and Chairman of the Board of Directors of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Dated: November 10, 2021 | /s/ Githesh Ramamurthy | |||||
Githesh Ramamurthy | ||||||
Chief Executive Officer |
Exhibit 32.2
Certification of Chief Financial Officer
Pursuant To Rule 18 U.S.C. Section 1350
In connection with the Quarterly Report on Form 10-Q of CCC Intelligent Solutions Holdings Inc. (the Company) for the period ended September 30, 2021, as filed with the U.S. Securities and Exchange Commission (the Report), I, Brian Herb, Executive Vice President, Chief Financial and Administrative Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Dated: November 10, 2021 | /s/ Brian Herb | |||||
Brian Herb | ||||||
Executive Vice President, Chief Financial and Administrative Officer |